Harnessing Large Language Models in Neonatal Intraventricular Hemorrhage: Exploring Retrieval Augmented Generation Methodology for Prognostic Variable Discovery.

Am J PerinatolMar 23, 2026 (epub)
Clinical ResearchPediatrics

Tanima Arora, Kristyn Beam

✦ AI-curated · Sources linked

In 30 seconds

This pilot study combined a systematic literature review with retrieval-augmented generation to assess whether GPT-4 and Claude Sonnet could identify and extract prognostic variables for intraventricular hemorrhage outcomes in preterm neonates. The models initially identified 39 studies; 28 met some or all validation criteria after hallucinated references were excluded. Across these studies, 14 predictors were identified in four outcome domains. Gestational age was mentioned 13 times (41%), birth weight 8 times (25%), and Apgar scores 11 times (34%). The authors also developed preliminary risk tiers, while emphasizing the need for human validation.

Key findings

  • Of 39 studies initially identified by the LLMs, 28 met some or all validation criteria after hallucinated references were excluded.
  • Fourteen prognostic predictors were extracted across mortality, progression, complications, and resolution outcomes.
  • Gestational age was mentioned 13 times (41%), birth weight 8 times (25%), and Apgar scores 11 times (34%).
  • The preliminary model estimated progression risk >70% and mortality >50% for neonates <28 weeks, <1,000g, and with Apgar <3.

Why it matters

The study suggests that retrieval-augmented LLMs may help organize published evidence and identify candidate prognostic variables for neonatal IVH. However, hallucinated references and incomplete synthesis show that automated extraction cannot be assumed reliable. Human review remains essential, particularly before using generated risk groupings to inform clinical decisions or developing decision-support tools.

What to keep in mind

This was a pilot study, and LLM outputs included hallucinated references and incomplete data synthesis. The authors also report no studies predicting resolution and limited investigation of complication predictors.

Source

Published in Am J Perinatol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Pediatrics

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.